Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + zimberelizumab in previously treated HER2-overexpressing biliary tract cancer
ChiCTR2200063838Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and zimberelimab in biliary cancer, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: objective response rate and adverse events. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
disitamab vedotinzimberelimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2200063838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063838.